-
1.发明授权
公开(公告)号：EP1919859B1
公开(公告)日：2010-06-02
申请号：EP06785134.5
申请日：2006-06-20
申请人： XenoPort, Inc.
发明人： JANDELEIT, Bernd , LI, Yunxiao , ZERANGUE, Noa , GALLOP, Mark, A.
IPC分类号： C07C271/22
CPC分类号： C07C271/22 , C07B2200/07 , C07C2601/14
-
2.发明公开ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE 有权ACYLOXYALKYLCARBAMAT-PRODRUGS VONTRANEXANSÄUREUND ANWENDUNG
公开(公告)号：EP1919859A2
公开(公告)日：2008-05-14
申请号：EP06785134.5
申请日：2006-06-20
申请人： Xenoport, Inc.
发明人： JANDELEIT, Bernd , LI, Yunxiao , ZERANGUE, Noa , GALLOP, Mark, A.
IPC分类号： C07C271/22
CPC分类号： C07C271/22 , C07B2200/07 , C07C2601/14
摘要： Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)- cyclohexanecarboxylic acid, pharmaceutical compositions thereof, methods of making prodrugs of trans-4-(aminomethyl)-cyclohexane-carboxylic acid, and methods of using prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof to treat or prevent various diseases or disorders are disclosed. Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)- cyclohexanecarboxylic acid and pharmaceutical compositions thereof suitable for oral and topical administration and for administration using sustained release dosage forms are also disclosed.
摘要翻译： 反式-4-（氨基甲基） - 环己烷羧酸的氨基甲酸烷氧基烷基酯前药，其药物组合物，制备反式-4-（氨基甲基） - 环己烷羧酸前体药物的方法，以及使用反式-4-（氨基甲基） - 环己烷羧酸及其药物组合物，用于治疗或预防各种疾病或病症。 还公开了反式-4-（氨基甲基） - 环己烷羧酸的氨基甲酸烷氧基烷基酯前药及其适用于口服和局部给药以及使用缓释剂型的给药的药物组合物。
-
3.发明公开COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE 审中-公开阿坎酸的药物前COMPLEX释放由PANTOSÄUREESTERNEOPENTYLSULFONYLESTERCYCLISIERUNG，THEREOF组合物及使用方法
公开(公告)号：EP2217564A1
公开(公告)日：2010-08-18
申请号：EP08829385.7
申请日：2008-09-05
申请人： XenoPort, Inc.
发明人： JANDELEIT, Bernd , LI, Yunxiao , GALLOP, Mark A. , ZERANGUE, Noa , VIRSIK, Peter A. , FISCHER, Wolf-Nicolas
IPC分类号： C07C309/15 , C07F9/09 , A61K31/255 , A61K31/661 , A61P25/00
CPC分类号： C07C309/15
摘要： Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate of formula (I), pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorders, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis and pain are disclosed.
-
-
搜索结果
3 条记录 (耗时 0.02 秒)
